Sumatriptan injection reduces productivity loss during a migraine attack: Results of a double-blind, placebo-controlled trial

Archives of Internal Medicine

Volumn 158, Issue 9, 1998, Pages 1013-1018

  Cady, Roger C ^a   Ryan, Robert ^c   Jhingran, Priti ^b   O'Quinn, Stephen ^b   Pait, D Gayla ^b  

^a HEADACHE CARE CENTER   (United States)

^b GLAXOSMITHKLINE   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SUMATRIPTAN SUCCINATE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CLASSIFICATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL TOXICITY; HOT FLUSH; HUMAN; INJECTION PAIN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MULTICENTER STUDY; OCCUPATION; PRIORITY JOURNAL; PRODUCTIVITY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RECURRENCE RISK; VERTIGO;

ADULT; DOUBLE-BLIND METHOD; EFFICIENCY; FEMALE; HUMANS; MALE; MIGRAINE DISORDERS; RECURRENCE; SELF ADMINISTRATION; SEVERITY OF ILLNESS INDEX; SUMATRIPTAN; TREATMENT OUTCOME; VASOCONSTRICTOR AGENTS; WORK;

EID: 0032507782     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.158.9.1013     Document Type: Article

References (14)

1. Stewart WF, Lipton RB, Celentano DD, et al. Prevalence of migraine headache in the United States: relation to age, income, race, and other sociodemographic factors. JAMA. 1992;267:64-69.
2. Stang PE, Osterhaus JT. Impact of migraine in the United States: data from the National Health Interview Survey. Headache. 1993;33:29-35.
3. Pryse-Phillips W, Findlay H, Tugwell P, Edmeads J, Murray TJ, Nelson RF. A Canadian population survey on the clinical, epidemiologic, and societal impact of migraine and tension-type headache. Can J Neurol Sci. 1992;19:333-339.
4. Osterhaus JT, Gutterman DL, Plachetka JR. Healthcare resource use and lost labor costs of migraine headache in the United States. Pharmacoeconomics. 1992;2:67-76.
5. Mushet GR, Miller DW, Clements B, Pait G, Gutterman DL. Impact of sumatriptan on workplace productivity, nonwork activities, and health-related quality of life among hospital employees with migraine. Headache. 1996;36:137-143.
6. Adelman JR, Sharfman M, Johnson R, et al. Impact of oral sumatriptan on workplace productivity, health-related quality of life, healthcare use, and patient satisfaction with medication in nurses with migraine. Am J Manage Care. 1996;2:1245-1254.
7. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 1988;8(suppl 7):1-98.
8. Drummond M. Cost-of-illness studies: a major headache! Pharmacoeconomics. 1992;2:5-7.
9. The Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. N Engl J Med. 1991;325:316-321.
10. Cady RK, Wendt JK, Kirchner JF, Sargent JD, Rothrock JF, Skaggs H. Treatment of acute migraine with subcutaneous sumatriptan. JAMA. 1991;265:2831-2835.
11. Schoenen J, Bulcke J, Caekebeke J, et al. Self-treatment of acute migraine with subcutaneous sumatriptan using an auto-injector device: comparison with customary treatment in an open, longitudinal study. Cephalalgia. 1994;14:55-63.
12. The Sumatriptan Auto-Injector Study Group. Self-treatment of acute migraine with subcutaneous sumatriptan using an auto-injector device. Eur Neurol. 1991;31:323-331.
13. Greiner DL, Addy SN. Sumatriptan use in a large group-model health maintenance organization. Am J Health Syst Pharm. 1996;53:633-638.
14. Jhingran P, Cady RK, Rubino J, Miller DW, Grice R, Gutterman DL. Improvements in health-related quality of life with sumatriptan treatment for migraine. J Fam Pract. 1996;42:36-42.